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Abstract
Purpose Case reports suggest that patients with previous gas-
tric bypass have an increased risk of severe hypocalcemia after
total thyroidectomy, but there are no population-based studies.
The prevalence of gastric bypass before thyroidectomy and
the risk of hypocalcemia after thyroidectomy in patients with
previous gastric bypass were investigated.
Methods By cross-linking The Scandinavian Quality Registry
for Thyroid, Parathyroid and Adrenal Surgery with the
Scandinavian Obesity Surgery Registry patients operated with
total thyroidectomy without concurrent or previous surgery
for hyperparathyroidism were identified and grouped accord-
ing to previous gastric bypass. The risk of treatment with
intravenous calcium during hospital stay, and with oral calci-
um and vitamin D at 6 weeks and 6 months postoperatively
was calculated by using multiple logistic regression in the
overall cohort and in a 1:1 nested case-control analysis.
Results We identified 6115 patients treated with total thyroid-
ectomy. Out of these, 25 (0.4 %) had undergone previous
gastric bypass surgery. In logistic regression, previous gastric
bypass was not associated with treatment with i.v. calcium
(OR 2.05, 95 % CI 0.48–8.74), or calcium and/or vitamin D
at 6 weeks (1.14 (0.39–3.35), 1.31 (0.39–4.42)) or 6 months
after total thyroidectomy (1.71 (0.40–7.32), 2.28 (0.53–9.75)).
In the nested case-control analysis, rates of treatment for hy-
pocalcemia were similar in patients with and without previous
gastric bypass.
Conclusion Previous gastric bypass surgery was infrequent in
patients undergoing total thyroidectomy and was not associ-
ated with an increased risk of postoperative hypocalcemia.
Keywords Total thyroidectomy . Gastric bypass .
Postoperative hypoparathyroidism . Cohort study
Introduction
Several case reports indicate that previous bariatric surgery for
morbid obesity constitutes a risk factor for severe hypocalce-
mia after total thyroidectomy (TT) [1–3]. Gastric bypass sur-
gery (GBP) is the most commonly performed procedure for
morbid obesity, and due to the worldwide obesity epidemic,
the prevalence of previous GBP is increasing [4].
Hypocalcemia is the most common complication of TT [5]
[6] and is caused by intraoperative injury to the parathyroid
glands or their blood supply [7]. Low level vitamin D can also
aggravate postoperative hypocalcemia [8]. Patients with GBP
are at risk of developing nutritional deficiencies [9] [10]. In
GBP, the absorption of calcium and vitamin D is diminished,
possibly due to the exclusion of the duodenum and proximal
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jejunum, where active vitamin D-associated calcium uptake
occurs [11]. Accordingly, patients with GBP have lower levels
of vitamin D (25OHD) than the general population [12].
However, it has been shown that 25OHD levels in GBP pa-
tients are equally low before and after GBP [13]. Low levels of
25OHD also persist at long-term follow up after GBP, together
with the increased levels of parathyroid hormone (PTH), de-
creased bone mineral density, and increased risk of fractures
[12–14]. This has led to the recommendation of calcium and
vitamin D supplementation after GBP [15]. Thus, patients
with previous GBP could be at increased risk of hypocalcemia
after TT.
Hypocalcemia after TT can cause unpleasant symptoms,
leading to increased costs for sick leave, follow-up visits,
and readmission [16] [17]. Therefore, identifying risk factors
for hypocalcemia is important. Patients with increased risk for
this complication could benefit from a longer hospital stay,
increased surveillance, and/or preoperative treatment with cal-
cium and/or vitamin D.
Apart from case reports [1–3], there has been no
population-based study investigating hypocalcemia after TT
in relation to GBP. Thus, we aimed to investigate the frequen-
cy and severity of postoperative hypocalcemia in patients with
previous GBP undergoing TT, and whether GBP increases the





The Scandinavian Quality Registry for Thyroid, Parathyroid
and Adrena l Su rge ry (SQRTPA, www. thy ro id -
parathyroidsurgery.com) started in 2004 and is recognized
by the Swedish National Board for Health and Social
Welfare as the national quality registry for endocrine surgical
procedures in Sweden. Currently, 35 Swedish units report to
the registry, covering 88 % of all procedures during the study
period. Coverage is assessed by calculating the proportion of
patients registered in the SQRTPA in relation to those regis-
tered in the Inpatient Register of the Swedish National Board
of Health and Welfare. The quality of data for the registered
patients is checked by external audit, comparing registered
data to hospital medical records. The audit has demonstrated
good data quality, with an error rate of <5 % [18, 19].
SOReg
The Swedish Obesity Registry, SOReg, started in May 2007.
All Swedish bariatric units are affiliated with this register. The
national coverage is 97 % and regular data quality evaluations
have shown that >98 % of data are correct [20].
Study cohort
Patients operated with TT between 1 January 2004 and 31
December 2015 were identified in the SQRTPA. Patients with
concurrent or previous surgery for hyperparathyroidism were
excluded, as were patients with missing information on post-
operative hypocalcemia. By cross-linking with the SOReg,
information on GBP was obtained.
Ethical considerations
This study was approved by the research ethics committee at
Lund University, DNR 2015/543 and 2016/83.
Data
Endpoint data concerning postoperative oral and intravenous
(i.v.) calcium and vitamin D treatment during hospital stay, at
discharge, and at 6 weeks and 6 months postoperatively were
extracted from the SQRTPA. Further, data on age, sex, indi-
cation for thyroidectomy, and lymph node dissection were
retrieved.
Statistical analysis
The risk of hypocalcemia after TT in patients with and without
previous GBP was investigated both in the whole cohort and
in a 1:1 nested case-control subset. In the nested case-control
group, patients with TT with previous GBP were randomly
matched to patients without previous GBP, on the factors age,
gender, lymph node dissection or not, and indication for
surgery.
Means and standard deviations (SD) were calculated for
continuous variables except for age. Age is reported asmedian
and range. Numbers and column percentages were calculated
for categorical variables.
In the whole cohort, risk for treatment with calcium and
vitamin D at different times of follow-up, in patients with and
without GBP, was investigated with uni- and multivariate lo-
gistic regression, adjusting for possible confounding vari-
ables: age, gender, indication for surgery, and lymph node
dissection. In the nested case-control subset, ANOVA, chi-
square, or Fisher’s exact tests were used to determine the
association of primary endpoints with previous GBP. All anal-
yses were performed with STATA 13 (StataCorp LP, College
Station, TX, USA). A p value of less than 0.05 was considered
statistically significant.
This study was performed and reported according to the
Strengthening the Reporting of Observational Studies in
Epidemiology statement [21].
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Results
Baseline patient and procedure characteristics
in the overall cohort
There were 7600 patients who underwent TT. Of these, we
excluded 217 patients due to prior or concurrent parathyroid-
ectomy. Another seven patients lacked information on treat-
ment for postoperative hypocalcemia. Patients that were oper-
ated before 1 May 2007 (start date of the SOReg) were also
excluded (N = 1261). This left 6115 patients for analysis. By
cross-linking with SOReg, 25 patients with GBP before TT
were identified, corresponding to a rate of 25/6115 (0.4 %).
The median age in the cohort was 46 (33–59), male to
female ratio was 1:4, and the indication for surgery was thy-
rotoxicosis in half of the patients. Mean (SD) postoperative
total calcium was 2.13 (±0.20; Table 1) at day one. Total
calcium at 6-week and 6-month follow-up were 2.30 (±0.17)
and 2.25 (±0.17), respectively. At 6-week follow-up, 841
(13.8 %) had oral calcium and 554 patients (9.1 %) vitamin
D substitution for hypocalcemia. These numbers were 290
(4.7 %) and 214 (3.5 %) at 6-month follow-up. Baseline char-
acteristics are summarized in Table 1.
The number of patients without follow-up information for
oral calcium treatment at 6 weeks and 6 months were 481
(7.9 %) and 641 (10.5 %), respectively.
Patient and procedure characteristics in patients with and
without previous GBP
In the whole cohort, there were no statistically significant
differences between patients with and without previous GBP
regarding age (median, (IQR)) 48 (41–52) vs 46 (33–59);
p = 0.977), male to female ratio (4/21 vs 1230/4860;
p = 0.602) and postoperative total calcium (mean, (SD) 2.13
(±0.16) mmol/l vs 2.12 (±0.20) mmol/l; p = 0.997). However,
there was a significant difference for the indication for thy-
roidectomy (p = 0.015). The most common indication for TT
overall was thyreotoxicosis; in patients with previous GBP, it
was compression symptoms.
Total serum calcium and rates of calcium and/or vitamin D
substitution at 6-week and 6-month follow-up after thyroidec-
tomy did not differ significantly between patients with and
without previous GBP in the whole cohort (Table 2).
Logistic regression analysis of hypocalcemia, vitamin D
and calcium treatment at discharge and follow-up
in the whole cohort
In the multivariate logistic regression analysis including age,
gender, lymph node dissection, and indication for surgery,
previous gastric bypass was not associated with in hospital
treatment with i.v. or oral calcium (2.07 (0.48–9.07); 0.89
(0.37–2.11)), oral calcium, and/or vitamin D at discharge
(0.75 (0.29–1.91); 1.37 (0.50–3.76)), at 6 weeks (1.11
(0.37–3.31); 1.25 (0.36–4.27)), or 6 months postoperatively
(1.45 (0.33–6.36); 2.01 (0.46–8.77); Tables 3 and 4).
Endpoints in patients with and without previous GBP
in the nested case-control group
For the matched nested case-control analysis, the 25 patients
with GBP before TT were successfully matched to an equal
Table 1 Characteristics of patients operated with total thyroidectomy
registered in the SQRTPA from 1 May 2007–2015 (N = 6115)
N = 6115 (100 %)





Recurrent cyst 12 (0.2)
Completion operation 17 (0.3)








Gland weight (grams) 74.2 (±94.0)







At discharge (yes/no) 1776 (29.0)/4339 (71.0)
At 6 weeks follow-up (yes/no) 841 (13.8)/4793 (78.4)
At 6 months follow-up (yes/no) 290 (4.7)/5184 (84.8)
Total serum calcium
Postoperative day 1 2.13 (±0.20)
At 6 weeks follow-up 2.30 (±0.17)
At 6 months follow-up 2.25 (±0.17)
Peroral vitamin D treatment
At discharge (yes/no) 909 (14.9)/5206 (85.1)
At 6 weeks follow-up (yes/no) 554 (9.1)/5087 (83.2)
At 6 months follow-up (yes/no) 214 (3.5)/5333 (87.2)
IQR interquartile range, GBP gastric bypass
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number of controls. Mean postoperative total calcium on day
one was 2.13 (±0.16) mmol/l in patients with previous GBP,
vs 2.16 (±0.15; p = 0.450) mmol/l in patients without. Mean
total serum calcium and rates of calcium and/or vitamin D
substitution at 6-week and 6-month follow-up after thyroidec-
tomy did not differ between patients with and without previ-
ous GBP (Table 5).
Discussion
Case reports and our own experience have suggested that pa-
tients with previous GBP suffer an increased risk of severe
hypocalcemia after TT [1–3], compared to patients without
GBP. GBP, the most common bariatric procedure, is associat-
ed with nutritional deficiencies [22], such as low levels of
25OHD and diminished uptake of dietary calcium. Low levels
of 25OHD have been shown to be a risk factor for postoper-
ative hypocalcemia after TT and central neck dissection [8].
An increased risk of hypocalcemia after TT with previous
GBP compared to TT without previous GBP is therefore
plausible.
However, the hypothesis that patients with previous GBP
have an increased risk of hypocalcemia after TT could not be
confirmed in this large, population-based, nationwide cohort
study. GBP was not a risk factor for hypocalcemia in uni- or
Table 2 Endpoint characteristics of group without and with previous GBP in the overall cohort (N = 6115)
No previous GBP N = 6090 (100 %) Previous GBP N = 25 (100 %) p value
Age median (IQR) 46 (33–59) 48 (41–52) 0.977
Sex
Male 1230 (20.2) 4 (16.0) 0.602
Female 4860 (79.8) 21 (84.0)
Indication for thyroidectomy
Recurrent cyst 12 (0.2) 0 (0.0) 0.015
Completion operation 17 (0.3) 0 (0.0)
Excluding malignancy 454 (7.5) 3 (12.0)
Malignancy 949 (15.6) 7 (28.0)
Compression 1575 (25.9) 11 (44.0)
Thyreotoxicosis 3059 (50.2) 4 (16.0)
Other 24 (0.4) 0 (0.0)
Lymphnode dissection
Yes 1061 (17.4) 7 (28.0) 0.164
No 5029 (82.6) 18 (72.0)
Gland weight (grams) 74.1 (±94.0) 80.7 (±72.2) 0.748
Oral perioperative calcium treatment
Yes 2047 (33.6) 8 (32.0) 0.865
No 4043 (66.4) 17 (68.0)
Intravenous calcium treatment
Yes 248 (4.1) 2 (8.0) 0.322
No 5842 (95.9) 23 (92.0)
Peroral calcium treatment
At discharge (yes/no) 1770 (29.1)/4320 (70.9) 6 (24.0)/19 (76.0) 0.578
At 6 weeks follow-up (yes/no) 837 (13.7)/4773 (78.4) 4 (16.0)/20 (80.0) 0.651
At 6 months follow-up (yes/no) 288 (4.7)/5163 (84.8) 2 (8.0)/21 (84.0) 0.373
Total serum calcium
Postoperative day 1 2.12 (±0.20) 2.13 (±0.16) 0.997
At 6 weeks follow-up 2.30 (±0.17) 2.27 (±0.13) 0.305
At 6 months follow-up 2.25 (±0.17) 2.26 (±0.10) 0.901
Peroral vitamin D treatment
At discharge (yes/no) 904 (14.8)/5186 (85.2) 5 (20.0)/20 (80.0) 0.470
At 6 weeks follow-up (yes/no) 551 (9.0)/5066 (83.2) 3 (12.0)/21 (84.0) 0.616
At 6 months follow-up (yes/no) 212 (3.5)/5311 (87.2) 2 (8.0)/22 (88.0) 0.278
IQR interquartile range, GBP gastric bypass
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multivariate logistic regression, and the rate of hypocalcemia
was similar between previous GBP and no previous GBP in a
nested case-control subset. Further, the frequency of previous
GBP in patients undergoing TTwas low, only 0.4 %.
The number of patients who underwent both first gastric
bypass surgery and then total thyroidectomy was low in this
study. However, taking into account that two nationwide reg-
isters, based on the whole Swedish population of about nine
million people, were used; we consider this finding a strength
rather than a weakness.
Another potential explanation for the lack of an association
could bemissing observations. The Swedish Obesity Register,
SOReg, started in May 2007, and no bariatric procedures per-
formed before this date could be included in our study. Hence,
it is possible that our study underestimates the rate of previous
GBP in patients with TT. However, this seems to be rather
unlikely since only 6–18 operations/100,000 were performed
2002–2006 and 24–89 operations/100,000 were performed
2007–2014 (Fig. 1S). Furthermore, the SOReg has a coverage
of almost 100 % and it is unlikely that GBPs performed after
Table 5 Results of 1:1 nested
case-control analysis No previous GBP N = 25
(100 %)
Previous GBP N = 25
(100 %)
p value
Age median (IQR) 48 (41–52) 48 (41–52) 1.000
Sex
Male 4 (16.0) 4 (16.0) 1.000
Female 21 (84.0) 21 (84.0)
Indication for thyroidectomy
Recurrent cyst 0 (0.0) 0 (0.0) 1.000
Completion operation 0 (0.0) 0 (0.0)
Excluding malignancy 3 (12.0) 3 (12.0)
Malignancy 7 (28.0) 7 (28.0)
Compression 11 (44.0) 11 (44.0)
Thyreotoxicosis 4 (16.0) 4 (16.0)
Other 0 (0.0) 0 (0.0)
Lymphnode dissection
Yes 7 (28.0) 7 (28.0) 1.000
No 18 (72.0) 18 (72.0)
Gland weight (grams) 74.0 (±61.7) 80.7 (±72.2) 0.737
Oral perioperative calcium treatment
Yes 10 (40.0) 8 (32.0) 0.556
No 15 (60.0) 17 (68.0)
Intravenous calcium treatment
Yes 0 (0.0) 2 (8.0) 0.149
No 25 (100.0) 23 (92.0)
Peroral calcium treatment
At discharge (yes/no) 8 (32.0)/17 (68.0) 6 (24.0)/19 (76.0) 0.935
At 6 weeks follow-up (yes/
no)
6 (24.0)/17 (68.0) 4 (16.0)/20 (80.0) 0.727
At 6 months follow-up (yes/
no)
2 (8.0)/20 (80.0) 2 (8.0)/21 (84.0) 0.599
Total serum calcium
Postoperative day 1 2.16 (±0.15) 2.13 (±0.16) 0.450
At 6 weeks follow-up 2.31 (±0.14) 2.27 (±0.13) 0.276
At 6 months follow-up 2.14 (±0.18) 2.26 (±0.10) 0.160
Peroral vitamin D treatment
At discharge (yes/no) 6 (24.0)/19 (76.0) 5 (20.0)/20 (80.0) 0.733
At 6 weeks follow-up (yes/
no)
4 (16.0)/19 (76.0) 3 (12.0)/21 (84.0) 0.329
At 6 months follow-up (yes/
no)
1 (4.0)/21 (84.0) 2 (8.0)/22 (88.0) 0.188
IQR interquartile range, GBP gastric bypass
278 Langenbecks Arch Surg (2017) 402:273–280
May 2007 were missed in the patients in the present study
[20].
The possibility of inaccurate data must also be taken into
account. If treatment for hypocalcemia is inaccurately report-
ed to the registry, the true frequency of this complication could
be underestimated. However, the SQRTPA is audited regular-
ly and data quality has been shown to be good. Further, data
on treatment for hypocalcemia would likely be missing or
inaccurate at random, and it is unlikely that this would sys-
tematically bias the results.
With only 25 patients with previous GBP, the study might
be underpowered to detect a true difference in the rate of
hypocalcemia after TT with and without previous GBP.
While we did not observe any difference, it must be empha-
sized that our study does not prove the absence of such a
difference.
The rate of calcium and/or vitamin D treatment in the
whole cohort and in the nested control group was rather high,
4.7 %. This high rate could make it difficult to detect a true
increase in the risk of hypocalcemia after TT in patients with
previous GBP. An explanation for the high rate of hypocalce-
mia in the whole cohort could be the inclusion of low-volume
hospitals in the registry. Another reason for the high rate of
hypocalcemia overall in this study could be the high propor-
tion of TT for thyrotoxicosis, more than 50 %, since previous
studies indicate that TT for thyrotoxicosis carries a higher risk
of long-term hypocalcemia. However, when adjusting for thy-
rotoxicosis in the multivariate logistic regression analysis,
there was no significant increased risk of hypocalcemia after
TT with previous GBP.
Another explanation for the disagreement with the present
study and previous case reports [1–3] could be that patients
with previous GBP in the present study had sufficient levels of
25OHD, and that patients in case reports had insufficient
levels of 25OHD. Unfortunately, we did not have information
about levels of 25OHD.
Furthermore, the time between GBP and TT could be im-
portant. Calcium and vitamin D depletion could aggravate
over time after GBP. Perhaps GBP does not increase the risk
of hypocalcemia after TT during the first years postoperative-
ly, and this might be another explanation to the lack of asso-
ciation between GBP and hypocalcemia after TT in our study,
since the time interval was in no patient longer than 7 years.
Similar to previous studies [23–25], age, gender, indication
for surgery, and lymph node dissection were risk factors for
postoperative hypocalcemia in our study.
The major strengths of this study include the large number
of patients with TT; the truly population-based design with
registers having wide national coverage; the high external va-
lidity including 35 Swedish units, ranging from small rural
county hospitals to large university hospitals; and the high
data quality in terms of coverage and accuracy, with nearly
100 % coverage for obesity surgery. Further, there were low
numbers of patients with missing information for oral calcium
treatment at 6 weeks and 6 months [18–20].
Conclusion
In conclusion, the results of this large observational study did
not provide evidence for an increased risk for hypocalcemia
after TT compared to patients without previous GBP. This
study does neither support giving any extra supplementation
to nor taking any extra blood tests in patients with previous
GBP before TT, since their risk of hypocalcemia does not
seem to markedly differ from the overall TT cohort.
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